Anti-CD24 antibodies that block the interaction with its ligand Siglec-10, expressed on macrophages and other innate immune cells, increase phagocytosis of cancer cells by macrophages, with encouraging results in early-phase clinical trials (9, 10). The gene discussed is CD24; the disease is cancer.